For example, the Oncotype DX 21-gene recurrence score is known to be a sound prognostic and predictive assay in node-negative hormonal receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer patients [31]. This evidence concerns the gene ERBB2 and breast carcinoma.